MetoHEXAL® Succ ® 23,75 mg Retardtabletten ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 113 | Muscular dystrophy | 1 |
113. Muscular dystrophy
Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-009871-36-DE (EUCTR) | 06/08/2009 | Study within children with Duchenne Muscular Dystrophy | Effect and Safety of preventive Treatment with ACE-Inhibitor and Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy - DMD-Kardio | Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: EnalHexal®, 5 mg INN or Proposed INN: ENALAPRIL Trade Name: EnaHexal®, 10mg INN or Proposed INN: ENALAPRIL Trade Name: MetoHEXAL® Succ ® 23,75 mg Retardtabletten INN or Proposed INN: METOPROLOL SUCCINATE Trade Name: MetoHEXAL® Succ ® 47,5 mg Retardtabletten INN or Proposed INN: METOPROLOL SUCCINATE Trade Name: MetoHEXAL® Succ ® 95 mg Retardtabletten INN or Proposed INN: METOPROLOL SUCCINATE | Friedrich- Alexander- Universität Erlangen Nürnberg | NULL | Not Recruiting | Female: no Male: yes | Germany |